Company: LCTX
Filing Date: 2025-03-10
Form Type: 10-K
Source: 0000950170-25-036309
Chunk: 261

Company: Lineage Cell Therapeutics, Inc.
Filing Date: 2025-03-10
Form: 10-K
Item: Item 8
Chunk 261
---
 attributable to Lineage   basic and diluted
     
    $
    (0.09
    )
     
    $
    (0.12
    )

    Weighted-average common shares used to compute basic and    diluted net loss per common share

    200,193

    172,663

See accompanying notes to the consolidated financial statements.

98

LINEAGE CELL THERAPEUTICS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(IN THOUSANDS)

    Year Ended December 31,

    2024

    2023

    NET LOSS
     
    $
    (18,582
    )
     
    $
    (21,479
    )

    Other comprehensive loss, net of tax:

    Foreign currency translation adjustment

    189

    353

    Unrealized gain on marketable debt securities

    3

    150

    COMPREHENSIVE LOSS

    (18,390
    )

    (20,976
    )

    Less: Comprehensive (income) loss attributable to    noncontrolling interest

    (27
    )

    (7
    )

    COMPREHENSIVE LOSS ATTRIBUTABLE TO LINEAGE    COMMON SHAREHOLDERS
     
    $
    (18,417
    )
     
    $
    (20,983
    )

See accompanying notes to the consolidated financial statements.

99

LINEAGE CELL THERAPEUTICS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY

(IN THOUSANDS)

    Accumulated

    Other

    Total

    Common Shares

    Accumulated

    Noncontrolling

    Comprehensive

    Shareholders’

    Shares

    Amount

    Deficit

    Deficit

    Income / (Loss)

    Equity

    BALANCE - December 31, 2022

    170,093

    $
    440,280

    $
    (363,370
    )
     
    $
    (1,403
    )
     
    $
    (3,571
    )
     
    $
    71,936

    Shares issued through ATM financing

    4,775

    6,625

    —

    —

    —

    6,625

    Financing